Futura Medical PLC (OTCPK:FAMDF)
$ 0.381 -0.034 (-8.19%) Market Cap: 120.65 Mil Enterprise Value: 115.75 Mil PE Ratio: 0 PB Ratio: 10.38 GF Score: 41/100

Full Year 2020 Futura Medical PLC Earnings Call Transcript

Apr 14, 2021 / NTS GMT
Release Date Price: $0.7
James Henry Barder
Futura Medical plc - CEO & Executive Director

Well, good morning, everybody, and welcome to the Futura Medical webcast for the year-end results 31st of December 2020. I'm James Barder, the Chief Executive, and I'm pleased to be joined today by Ken James, who's Executive Director and Head of R&D; and Angela Hildreth, who's Finance Director and Chief Operating Officer.

Can we please turn to the next slide? First of all, a bit of a corporate overview about Futura. We're listed on AIM. We describe ourselves as a virtual organization with 15 staff members and a number of consultants, 30 consultants. Our key asset is DermaSys. Our real expertise is in transdermal science, development of topical gels. We have a track record of clinically-proven innovation, both in sexual health and pain relief. And we have a portfolio of late-stage products with an experienced management team.

Today, we're talking about 3 of our products. Obviously, the main focus is MED3000, which is a topical gel for erectile dysfunction. Ken will also talk a little bit later on about 2 other gels

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot